This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Gilead Sciences, Inc., Nurix Therapeutics, Inc.. Active years: 2024-2026.
Company Filing History:
2 out of 946 
1 out of 22 Years Active: 2024-2026
Title: Tim Kane - Innovator in Biotechnology
Introduction
Tim Kane is a talented inventor based in San Francisco, California. With a specific focus on biopharmaceutical innovations, he has made significant contributions to the field through his patented work that explores new therapeutic approaches.
Latest Patents
Tim Kane holds a notable patent for "Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases." This innovative patent presents bifunctional compounds that serve as IRAK4 degraders via the ubiquitin proteasome pathway. It further outlines methods for treating diseases modulated by IRAK4, showcasing the potential for novel treatment options.
Career Highlights
Currently, Tim Kane is affiliated with Gilead Sciences, Inc., a leading company in the biopharmaceutical industry. His expertise and innovative approach contribute significantly to the company’s mission to develop advanced therapeutic solutions.
Collaborations
In his professional journey, Tim has collaborated with esteemed colleagues, including Wylie Palmer and Jeffrey Wu. Together, they work on pushing the boundaries of biopharmaceutical research and development, enhancing the potential for impactful medical advancements.
Conclusion
With his groundbreaking patent and active role at Gilead Sciences, Tim Kane exemplifies the spirit of innovation within the biotechnology sector. His work not only advances scientific understanding but also paves the way for future therapies, reflecting a commitment to improving patient outcomes.